Skip to main content

Table 1 The baseline characteristics of all selected patients with hepatocellular carcinoma (HCC)

From: Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization

Characteristic

Total ( n  = 224)

 

Antiviral treatment group ( n  = 80)

Non-antiviral treatment group ( n  = 144)

P value c

Sex (males:females)

  209:15

 

78:2

 131:13

0.092

Age (years) a

49.5 (38.5, 58.0)

 

48.0 (39.5, 56.0)

50.5 (38.0, 59.0)

0.574

WBC (×10 9 /L)

6.66 ± 2.12

 

6.38 ± 1.85

6.82 ± 2.25

0.286

HBG (g/L)

137.91 ± 20.28

 

137.90 ± 22.36

137.90 ± 19.10

0.987

PLT (×10 9 /L)

179.91 ± 84.16

 

170.30 ± 88.10

185.24 ± 81.71

0.076

ALT (U/L)

58.38 ± 40.62

 

65.28 ± 44.99

54.54 ± 37.60

0.081

AST (U/L)

84.89 ± 62.44

 

91.17 ± 63.80

81.40 ± 61.62

0.125

ALB (g/L)

40.10 ± 4.40

 

39.30 ± 4.55

40.54 ± 4.26

0.032

TBIL (μmol/L)

16.44 ± 7.61

 

17.73 ± 8.49

15.72 ± 6.99

0.059

AFP (ng/mL) a

1301 (50, 38,398)

 

1436 (53, 37,546)

1210 (50.74, 39,410)

0.820

AFP (<1,000 ng/mL:>1,000 ng/mL)

    108:116

 

  39:41

   69:75

0.905

PT (s)

12.58 ± 2.08

 

12.83 ± 2.05

12.44 ± 2.09

0.052

APPT (s)

27.95 ± 3.85

 

28.22 ± 3.69

27.80 ± 3.94

0.278

HBeAg (positive:negative)

      53:171

 

  24:56

     29:115

0.096

HBV DNA (log 10 IU/mL)

4.85 ± 1.86

 

5.50 ± 1.58

4.48 ± 1.92

<0.001

UICC TNM stage (I:II:IIIa:IIIb + IIIc:IV)

46:25:68:63:22

 

9:14:25:26:6

37:11:43:37:16

0.024

TNM stage (early:advanced)

       71:153

 

  23:57

   48:96

0.480

Cycles of TACE (one:more than one)

  133:91

 

  37:43

   96:48

0.003

Resection after TACE (yes:no)

       19:205

 

    7:73

     12:132

0.915

Local ablation after TACE (yes:no)

       49:175

 

  23:57

     26:118

0.064

Sorafenib therapy after TACE (yes: no)

       12:212

 

     6:74

     6:138

0.288

Subsequent therapy b after TACE (yes:no)

       67:157

 

  30:50

     37:107

0.065

Chemotherapeutic agents

(epirubicin only:>2 agents)

       53:171

 

  18:62

     35:109

0.761

  1. aThe values are presented as median followed by interquartile (P25 and P75) in the parentheses. bSubsequent therapy means any treatment after TACE, including resection, local ablation, or sorafenib therapy. cDifferences between the antivirus group and the non-antivirus group. WBC, white blood cells; HBG, hemoglobin; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; AFP, α-fetoprotein; PT, prothrombin time; APTT, activated partial thromboplastin time; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; UICC TNM, International Union Against Cancer tumor-node-metastasis; TACE, transcatheter arterial chemoembolization.
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us